All News
Do probiotics improve psoriatic arthritis?
Unfortunately no difference in disease activity compared to placebo.
Limited effects on gut dysbiosis
Minor effects on T cell composition
@RheumNow #ACR23 Abs#0778 https://t.co/JuBesyfnV2
Robert B Chao, MD ( View Tweet)
Targeted OX40L (co-stimulatory APC protein w/ possible polymorphisms in SLE) study by Womba et al, found OX40L targeted CAR-Tregs had superior in vitro suppression of activated T cells & dendritic cells relative to Control-Tregs. #ACR23 Abs 0799 https://t.co/GgCGGIvhHF @rheumnow https://t.co/GZMEUCTooh
Dr. Rachel Tate ( View Tweet)
Should the cost of #CAR-T stop us from considering in severe refractory #lupus? So far update of German group show remission - drug free and great safety. But hold on..we need RCTs with an active control and longer f/u, but I am impressed! #ACR23 #ACRbest @ACRheum @RheumNow #784 https://t.co/mRMWLCbpCY
Janet Pope ( View Tweet)
Klein et al. 205 RA-ILD. MUC5B not significantly associated survival, although wide CIs, aHR 0.75 (0.45, 1.24). Abstr#0772 #ACR23 @RheumNow https://t.co/ZfIIr2BbbR https://t.co/47DPYWNpL9
Richard Conway ( View Tweet)
#ACR23 tidbits from Sunday @ACRheum @RheumNow
1 Less steroids better w other #Rx in #GCA, #PMR, #SLE #nephritis, #nonrenal #lupus BUT NOT in Severe GCA
2 Trend for combined immune modulators in #lupus GN or w a #CNI
3 #HCQ is better than sliced bread in #SLE aim for drug level
Janet Pope ( View Tweet)
#ACR23
Lower persistance of TNFi in women than men in Psa👍🇫🇷🇫🇷🇫🇷 CHU Mondor
@RheumNow https://t.co/27OVLz4aZN
Dellal ( View Tweet)
Biologic persistance rates consistently lower in women vs men with PsA. 52% vs 62% @ 1 year. Some statistically significant, but really it is a consistent message across drugs. We urgently need research on the reasons. Abstr#0779 #ACR23 @RheumNow https://t.co/Kfk3k3LJ44 https://t.co/SmiOnt7D4d
Richard Conway ( View Tweet)
Risk factor for 1st Thrombosis in OB APS
Ab#0115 #ACR23 @RheumNow
186 OAPS pts, followed mean 5.4 yrs. 11 thrombotic events
Risk factors: Triple pos APS Abs (OR 11.6), hypocomplementemia (OR 9)
Low dose Aspirin (OR 0.14), HCQ (OR 0.11) reduced thrombosis
#ACRBest https://t.co/y4KaEAZzA7
Eric Dein ( View Tweet)
🆕 Imaging modality: MSOT multispectral optoacoustic tomography
Findings PsA enthesis
-Hyperemia ↗️ oxygenation So2 and Hboxy
-Reduction Collagen concentration
-Lipids substitution
But surprise PSO pts display similar signs despite abs of symptoms!
@RheumNow ABST0750 #ACR23 https://t.co/qWMvmIRd7j
Aurelie Najm ( View Tweet)
#ACR23 Convergence Preview
https://t.co/oCdYnS1HdC https://t.co/A6klTchrrG
Dr. John Cush RheumNow ( View Tweet)
FAPα possible therapeutic biomarker target of pathogenic fibroblasts. #ACR23 Abs 0802 demonstrates potential therapeutic efficacy of fibroblast-targeted immunotherapy as a novel treatment in inflammatory disease. https://t.co/ZGUfC6PZxa @rheumnow https://t.co/jj9BeuvTuc
Dr. Rachel Tate ( View Tweet)
Abs#518 @RheumNow #ACR23
Deodhar: TOFA in AS, by b/l CRP levels
30% nml CRP (<5 mg/L) v 70% Elevated
At wk 12, TOFA >> PBO regardless of b/l CRP
Difference in response: greater in pts w elevated CRP
Safety rates: elev. CRP c/w PBO, but nml CRP had trend of high AEs for tofa v PBO https://t.co/b9NRNkU8ub
Eric Dein ( View Tweet)
Are Long-term NSAIDs safe in AS?
Ab#0528 #ACR23 @RheumNow
19,775 AS pts vs 59,325 controls.
Incidence of 16.9, 13.8 per 1,000 person-yrs, respectively
Long-term use of NSAIDs increased risk of CVD in non-AS control (aHR 1.64), but did NOT in AS pts (aHR 1.06)
Eric Dein ( View Tweet)
Differences in #glucocorticoid dosing. In #lupus #nephritis less steroids are the same as high dose steroids. Placebo arms of pooled data from #LN #RCTs. Less is equal! #ACRbest #ACR2023 @RheumNow @ACRheum abst0781 High dose steroids tended to have lower MMF doses https://t.co/XwTlsy4xKE
Janet Pope ( View Tweet)
Plasma MMPs and RA-ILD. Strong association MMPs 7 & 9 with prevalent RA-ILD. Abstr#0770 #ACR23 @RheumNow https://t.co/5qWeK3lAly https://t.co/SyZY2OhcbH
Richard Conway ( View Tweet)
2 yrs extension of DRESS-PS study
100+ pts w/ PsA and AxSPA
-70% LDA state in both Ctrl & Intervention gps
-strong recovery after relapse
No difference efficacy protocolized & routine care tapering but inferior TNFi use (52 vs. 77%) in Intervention gp
@RheumNow #ACR23 ABST0775 https://t.co/V2DqCjT0w3
Aurelie Najm ( View Tweet)
#ACR23
IV secukinumab vs placebo at 52 Weeks
@RheumNow https://t.co/4zQa37tN4l
Dellal ( View Tweet)
Abs#0608 #ACR23 @RheumNow
Cenerimod: sphigosine 1-phos (S1P) 1 receptor modulator for SLE
P2 CARE Study
51% of pts had high IFN1 sign., ass w/ high dsDNA
Cenerimod 4 mg: decreased dsDNA and IFN-a protein at 6 mo vs b/l
In high IFN pts, 4 mg Cen: decrease SLEDAI, SRI-4
Eric Dein ( View Tweet)
Abs#595 #ACR23 @RheumNow
R Furie on 4 yr TULIP-LTE pts with b/l renal involvement
33% on anifrolumab continued to wk 208 vs PBO 6%
Renal improvement at w208 in 9/10 pts, vs no avail PBO data
Conclusion: more Anifrolumab pts remained in study & reached SLEDAI-2K renal improvement
Eric Dein ( View Tweet)
Cowley et al @sharoncowley01 Subclinical GCA in 17.5% with new PMR. Males with higher ESR more likely to have subclinical GCA. Subclinical GCA more axillary artery. Abstr#0747 #ACR23 #ACRbest @RheumNow https://t.co/CghmX1TKpf https://t.co/MJawtslLud
Richard Conway ( View Tweet)